Mylan settles patent litigation with Novo Nordisk over generic Ozempic in United States – Healthcare News

NATCO Pharma Ltd on Monday announced that its partner Mylan Pharmaceuticals Inc has reached a patent litigation settlement with Novo Nordisk in the US over generic Ozempic, a drug used to lower blood sugar and weight loss.

According to a report by news agency PTI, NATCO and Mylan have partnered for the development of generic Ozempic (Semaglutide) products, the company said in a regulatory filing. Ozempic is a prescription medication patented by Novo Nordisk.

“Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide),” NATCO said in the filing. The terms of the settlement are confidential, it added.

Why are markets falling? Here are 5 reasons why Sensex, Nifty are under selling pressure

Bitter pill for pharma: Growth worries plague most companies in August, green shoots expected in FY25

After CDSCO flagged 53 commonly used medicines for failing quality test, pharma body defends its member companies

DCGI suspends approval of Entod Pharmaceuticals’ eye drop after it claimed to reduce dependency on reading glasses

Novo Nordisk had filed a patent infringement suit against Mylan over Ozempic in a US court.

(With inputs from PTI)